Brief: Paratek Pharmaceuticals Announces FDA Orphan Drug Designation For Nuzyra For The Treatment Of Infections Caused By Nontuberculous Mycobacteria
18/08/2021 21:43
Aug 18 (Reuters) - Paratek Pharmaceuticals Inc PRTK.O :
* PARATEK PHARMACEUTICALS ANNOUNCES FDA ORPHAN DRUG
DESIGNATION
FOR NUZYRA® (OMADACYCLINE) FOR THE TREATMENT OF INFECTIONS
CAUSED BY NONTUBERCULOUS MYCOBACTERIA
Source text for Eikon: ID:nGNX5qGMJC
Further company coverage: PRTK.O
Recent news on Paratek Pharmaceuticals
See all newsNovo Holdings closes $462 mln acquisition of Paratek Pharmaceuticals
Brief: Glass Lewis Recommends Paratek Pharmaceuticals Stockholders Vote For Acquisition By Gurnet Point Capital And Novo Holdings
Brief: Paratek Pharmaceuticals Responds to Demand Letters From 11 Stockholders Alleging 'Misleading', Incomplete Statements In Proxy Statement Filed On June 30
Brief: Independent Proxy Advisory Firm ISS Recommends Paratek Pharmaceuticals Stockholders Vote For Acquisition By Gurnet Point Capital And Novo Holdings
Brief: Paratek Pharmaceuticals Announces Second Quarter 2023 Revenue Of $40.0 Million